Sign in
Taking people in United StatesNo phase

Perinatal tissue grafts added to usual care for diabetic foot ulcers that won't heal

Tests perinatal tissue grafts plus usual care for non-healing diabetic foot ulcers.

Key facts

Who runs it
Samaritan Biologics
Where
Monroe, United StatesSee the site
Trial code
Registry title
Evaluating the Efficacy of Perinatal Membrane Allografts in Addition to the Standard of Care for the Treatment of Non-healing Diabetic Foot Ulcers.
Status
Recruiting
People taking part
170 people, planned
Started
9 May 2025
Expected to end
Mar 2027
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Dual-layer perinatal tissue allograft
  • Three-layer fenestrated perinatal tissue allograft
  • Standard of care
Record updated
2 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 1 or 2 diabetes who have a foot ulcer that has not healed. It compares standard wound care alone with standard care plus perinatal tissue grafts.

Age
18 years or older
Sex
All sexes can join
Disease stage
One ulcer on the foot, Wagner grade 1 or 2, from 1.0 cm2 to 20.0 cm2 after cleaning. It must have been present for 4 to 52 weeks of standard care. At least 50% of it must lie below the ankle bone. No tendon or bone may be exposed. Blood flow to the leg must be good enough on a vascular test. Ulcers on the sole must have had pressure taken off for at least 14 days.
Earlier treatment
Standard wound care for at least 4 weeks before screening. No hyperbaric oxygen therapy or CAMP product in the 30 days before screening. No steroid cream on the ulcer in the month before screening.
Biomarker or test result
HbA1c must be below 12% (108 mmol/mol) within 3 months of screening.

Main reasons for not taking part

  • Infected ulcer, skin infection around it, bone infection, or infection needing antibiotics by mouth or vein
  • Taking drugs that weaken the immune system (including more than 10 mg of Prednisone per day) or chemotherapy
  • Ulcer shrank by 20% or more in the 2 weeks before screening or during the 2-week screening phase
  • Kidney failure needing dialysis, or a life expectancy under 6 months
  • Pregnant or planning pregnancy within 6 months, or malnourished (MNA score under 17)

The registry criteria, word for word

Show all 32 criteriaShow less

Who can take part

  • Potential subjects are required to meet all the following criteria for enrollment in the study
  • Subjects must be at least 18 years of age or older
  • Subjects must have a diagnosis of type 1 or 2 Diabetes mellitus
  • At randomization subjects must have a target ulcer with a minimum surface area of 1.0 cm2 and a maximum surface area of 20.0 cm2 measured post debridement
  • The target ulcer must have been present for a minimum of 4 weeks and a maximum of 52 weeks of standard of care, prior to the initial screening visit
  • The target ulcer must be located on the foot with at least 50% of the ulcer below the malleolus
  • The target ulcer must be Wagner 1 or 2 grade, extending at least through the dermis or subcutaneous tissue and may involve the muscle provided it is below the medial aspect of the malleolus. The ulcer may not include exposed tendon or bone
  • The affected limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 3 months of the first screening visit are acceptable:; ABI between 0.7 and ≤ 1.3; TBI ≥ 0.6; TCOM ≥ 40 mmHg; PVR: biphasic
  • If the subject has two or more ulcers, they must be separated by at least 2 cm. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer
  • Target ulcers located on the plantar aspect of the foot must be offloaded for at least 14 days prior to enrollment
  • The potential subject must consent to using the prescribed offloading method for the duration of the study
  • The potential subject must agree to attend the weekly study visits required by the protocol
  • The potential subject must be willing and able to participate in the informed consent process

Who cannot take part

  • A subject receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of Prednisone per day or equivalent) or cytotoxic chemotherapy is excluded
  • A subject with a previous partial amputation on the affected foot is excluded if the resulting deformity impedes proper offloading of the target ulcer
  • The subject is excluded if the surface area of the target ulcer has reduced in size by more than 20% in the 2 weeks prior to the initial screening visit ("historical" run-in period). Photographic planimetry is not required for measurements taken during the historical run-in period (e.g. calculating surface area using length x width is acceptable)
  • The subject is excluded if the surface area measurement of the Target ulcer decreases by 20% or more during the 2-week screening phase: the 2 weeks from the initial screening visit (S1) to the TV-1/randomization visit, during which time the subject received SOC
  • Participation in a clinical trial involving treatment with an investigational product within the previous 30 days
  • A Subject treated with hyperbaric oxygen therapy or a Cellular Acellular, or Matrix-like Product (CAMP) in the 30 days prior to the initial screening visit is excluded
  • The subject is excluded if the target ulcer is not secondary to diabetes
  • If the target ulcer is infected or if there is cellulitis in the surrounding skin, the subject is excluded
  • If there is evidence of osteomyelitis complicating the target ulcer, the subject is excluded
  • A potential subject cannot have an infection in the target ulcer or in a remote location that requires systemic antibiotic therapy
  • The topical application of steroids to the ulcer surface within one month of initial screening is not permitted
  • A subject with an acute Charcot foot, or an inactive Charcot foot, that impedes proper offloading of the target ulcer is excluded
  • A potential subject with end stage renal disease requiring dialysis is excluded
  • A subject who, in the opinion of the investigator, has a medical or psychological condition that may interfere with study assessments is excluded
  • The potential subject has glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit
  • Potential subjects meeting any of the following criteria will be excluded from enrollment in the study
  • A subject known to have a life expectancy of < 6 months is excluded
  • Women who are pregnant or considering becoming pregnant within the next 6 months are excluded
  • A subject is excluded if they are malnourished: a score of less than 17 on the Mini Nutritional Assessment (MNA)

Where in United States

  • Monroe Biomedical ResearchMonroe, United StatesContact: Krista GrossTaking people

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn if using perinatal tissue allografts improves healing of chronic, non-healing foot ulcers in diabetic patients.

Read full original descriptionShow less

The main question that this study aims to answer is:

Does the use of perinatal tissue allografts in conjunction with standard of care wound management techniques result in a higher percentage of target ulcers achieving complete closure (i.e. healing) as compared to ulcers being treated with standard of care alone after 12 weeks of treatment.

One ulcer on each participant's foot will receive weekly 1) applications of perinatal tissue allografts and standard of care wound management or 2) standard of care wound management alone. Pictures of the ulcer and measurements of its size will be measured every week to track its healing progress over a total treatment period of 12 weeks. Additionally, the participants will be asked to fill out a questionnaire about the wound impacts their life and their quality of life.

The 3 groups in the trial

  • Dual-layer perinatal tissue allograftTreatment being tested

    Patients will receive weekly applications of a dual-layer perinatal tissue allograft in addition to standard of care wound management.

    Treatment: Dual-layer perinatal tissue allograft and Standard of care

  • Three-layer fenestrated perinatal tissue allograftTreatment being tested

    Patients will receive weekly applications of a three-layer fenestrated perinatal tissue allograft in addition to standard of care wound management.

    Treatment: Three-layer fenestrated perinatal tissue allograft and Standard of care

  • Standard of care (SOC) wound managementExisting treatment, for comparison

    Standard of care (SOC) will include cleansing of the index wound with sterile normal saline solution, followed by sharp debridement to remove necrotic tissue, application of appropriate dressings and wound off-loading.

    Treatment: Standard of care

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Multicenter, Prospective, Randomized Controlled Modified Platform Trial Evaluating the Efficacy of Multiple Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Standard of Care Alone in the Treatment of Nonhealing Diabetic Foot Ulcers.
Plain-language title
Perinatal tissue grafts added to usual care for diabetic foot ulcers that won't healGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
2 September 2026